Enkaid - General Information

All drug products containing encainide hydrochloride. Enkaid hydrochloride, formerly marketed as Enkaid capsules, was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack. The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.


Pharmacology of Enkaid

Used to treat irregular heartbeats, encainide decreases excitability, conduction velocity, and automaticity as a result of slowed atrial, atrioventricular (AV) nodal, His-Purkinje, and intraventricular conduction. It causes a slight but significant prolongation of refractory periods in these tissues. The greatest effect is on the His-Purkinje system. Enkaid decreases the rate of rise of the action potential without markedly affecting its duration.


Additional information about Enkaid

Enkaid Indication: For management of irregular heartbeats to a normal rhythm.
Mechanism Of Action: Enkaid is a sodium channel blocker, binding to voltage gated sodium channels. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses. Ventricular excitability is depressed and the stimulation threshold of the ventricle is increased during diastole.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Encainide
Synonyms: Encainida [Spanish]; Encainide [French]; Encainidum [Latin]
Drug Category: Antiarrhythmic Agents
Drug Type: Small Molecule; Approved; Withdrawn

Other Brand Names containing Encainide: Enkaid;
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Not Available
Half Life: 1-2 hours
Dosage Forms of Enkaid: Not Available
Chemical IUPAC Name: 4-methoxy-N-[2-(1-piperidin-1-ylpropan-2-yl)phenyl]benzamide
Chemical Formula: C22H28N2O2
Encainide on Wikipedia:
Organisms Affected: Humans and other mammals